A novel biomarker assay qualification strategy for rare human matrices – a case study of biomarkers in aqueous humor

References

• FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. US FDA, MD, USA. http://www.ncbi.nlm.nih.gov/books/NBK326791/
   Google Scholar
• Kaur S, Alley SC, Szapacs M et al. 2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A – Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B – Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine). Bioanalysis 14(9), 505–580 (2022).
   PubMed Web of Science ®Google Scholar
• Dubiel EA, Myler H, Arnold ME et al. Biological matrix supply chain shortages: more matrices are now rare-the case for surrogate matrices. AAPS J. 24(2), 42 (2022).
   PubMed Web of Science ®Google Scholar
• Tamhane M. Review of biomarkers in ocular matrices: challenges and opportunities. Pharm. Res. 36(3), 35 (2019).
   PubMed Web of Science ®Google Scholar
• Heinig K, Bertran E, Potter J, Fraier D. Ocular bioanalysis: challenges and advancements in recent years for these rare matrices. Bioanalysis 9(24), 1997–2014 (2017).
   PubMed Web of Science ®Google Scholar
• Göpfert JC, Reiser A, Carcamo Yañez VA et al. Development and evaluation of an ultrasensitive free VEGF-A immunoassay for analysis of human aqueous humor. Bioanalysis 11(9), 875–886 (2019).
   PubMed Web of Science ®Google Scholar
• Tom I, Pham VC, Katschke KJ et al. Development of a therapeutic anti-HtrA1 antibody and the identification of DKK3 as a pharmacodynamic biomarker in geographic atrophy. Proc. Natl Acad. Sci. USA 117(18), 9952–9963 (2020).
   PubMed Web of Science ®Google Scholar
• Genentech. Maass, Katie. 2019 AAPS PharmSci 360. https://www.eventscribe.com/2019/PharmSci360/fsPopup.asp?efp=SUlFUEhHSFQ4MDkx&PosterID=235059&rnd=0.8233907&mode=posterinfo
   Google Scholar
• Cowan K, Gao X, Parab V et al. Fit-for-purpose biomarker immunoassay qualification and validation: three case studies. Bioanalysis 8(22), 2329–2340 (2016).
   PubMed Web of Science ®Google Scholar
• Arnold ME, Booth B, King L, Ray C. Workshop report: Crystal City VI-bioanalytical method validation for biomarkers. AAPS J. 18(6), 1366–1372 (2016).
   PubMed Web of Science ®Google Scholar
• Timmerman P, Herling C, Stoellner D et al. European Bioanalysis Forum recommendation on method establishment and bioanalysis of biomarkers in support of drug development. Bioanalysis 4(15), 1883–1894 (2012).
   PubMed Web of Science ®Google Scholar
• Khan MU, Bowsher RR, Cameron M et al. Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development. Bioanalysis 7(2), 229–242 (2015).
   PubMed Web of Science ®Google Scholar
• Jani D, Allinson J, Berisha F et al. Recommendations for use and fit-for-purpose validation of biomarker multiplex ligand binding assays in drug development. AAPS J. 18(1), 1–14 (2015).
   PubMed Web of Science ®Google Scholar
• Piccoli SP, Mehta D, Vitaliti A et al. 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation(Part 3 – Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62). Bioanalysis 11(24), 2207 (2019).
   PubMed Web of Science ®Google Scholar
• Fischer SK, Carrasco-Triguero M, Hong K et al. Commercial biomarker assays: friend and foe. Bioanalysis 8(22), 2351–2362 (2016).
   PubMed Web of Science ®Google Scholar
• Lee JW, Devanarayan V, Barrett YC et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23(2), 312–328 (2006).
   PubMed Web of Science ®Google Scholar
• Tripathi RC, Millard CB, Tripathi BJ. Protein composition of human aqueous humor: SDS-PAGE analysis of surgical and post-mortem samples. Experiment. Eye Res. 48(1), 117–130 (1989).
   PubMed Web of Science ®Google Scholar
• Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor dynamics: a review. Open Ophthalmol. J. 4, 52–59 (2010).
   PubMedGoogle Scholar
• Leeman M, Choi J, Hansson S, Storm MU, Nilsson L. Proteins and antibodies in serum, plasma, and whole blood-size characterization using asymmetrical flow field-flow fractionation (AF4). Anal. Bioanal. Chem. 410(20), 4867–4873 (2018).
   PubMed Web of Science ®Google Scholar
• Gupta V, Davancaze T, Good J et al. Bioanalytical qualification of clinical biomarker assays in plasma using a novel multi-analyte Simple Plex™ platform. Bioanalysis 8(23), 2415–2428 (2016).
   PubMed Web of Science ®Google Scholar
• Cowan K, Golob M, Goodman J et al. Biomarker context-of-use: how organizational design can impact the implementation of the appropriate biomarker assay strategy. Bioanalysis 14(13), 911–917 (2022). • Considerations when defining context of use for a biomarker assay.
   PubMed Web of Science ®Google Scholar
• Velagaleti PR, Buonarati MH. Challenges and strategies in drug residue measurement (bioanalysis) of ocular tissues. Methods Pharmacol. Toxicol. doi: 10.1007/7653-2013-6 (2014).
   Google Scholar
• da Silva PHR, Júnior AdSC, Pianetti GA, Fernandes C. Chromatographic bioanalysis of antiglaucoma drugs in ocular tissues. J. Chromatog. B. 1166, 122388 (2021).
   PubMed Web of Science ®Google Scholar
• Olsson M, Årlig J, Hedner J, Blennow K, Zetterberg H. Repeated lumbar punctures within 3 days may affect CSF biomarker levels. Fluids Barriers CNS 16(1), 37 (2019).
   PubMed Web of Science ®Google Scholar